The new patent is titled ‘Regioselective and Stereoselective Oxidation of Fused Ring Systems Useful for the Preparation of Aminosterols’. It marks the first patent issued for this intellectual property and it expires in 2023.
Irach Taraporewala, CEO of Ohr Pharmaceutical, said: “Our new synthesis method is not only more cost-effective, but is also more scalable. It shortens the manufacturing process by eliminating steps and the need for purification. Manufacturing advances and the intellectual property surrounding them not only add value to the company’s efforts towards US FDA approval, but also create additional barriers to competition.
“This new patent strengthens our position as we continue development of our two later stage lead drugs, Evizon and OHR/AVR 118 for the treatment of Cancer Cachexia, a severe wasting disorder associated with late stage cancer patients. We look forward to continuing this development and bringing our pipeline of drugs to market.”